Investor Firms Press Baxter Securities Case Over Novum Pump as Dec. 15 Lead-Plaintiff Deadline Nears

Notices center on alleged failures to disclose Novum pump safety risks preceding a July shipment pause.

Overview

Faruqi & Faruqi issued a Nov. 8 reminder that investors have until December 15, 2025 to seek appointment as lead plaintiff in the filed federal securities class action.
Bernstein Liebhard and Lowey Dannenberg announced actions on behalf of investors who bought Baxter shares between February 23, 2022 and July 30, 2025.
Complaints allege the Novum IQ/LVP infusion pump had systemic defects causing underinfusion, overinfusion, or non-delivery, with reports of injuries and deaths.
Filings cite Baxter’s July 31, 2025 announcement pausing Novum LVP shipments with no restart date, followed by a reported 22.4% stock drop to $21.76 that day.
Most notices use the February 23, 2022–July 30, 2025 class period, though a Schall Law Firm alert references a different earlier window.